Neuronetics, Inc.
2.9000-0.20 (-6.45%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · STIM · USD
Key Stats
Market Cap
191.76MP/E (TTM)
-Basic EPS (TTM)
-1.15Dividend Yield
0%Recent Filings
8-K
Neuronetics draws $10M funding
Neuronetics secured $10 million in additional funding via Amendment No. 3 to its Perceptive credit facility on August 1, 2025, triggered by meeting $85 million net revenue for the four quarters ended June 30, 2025. This bolsters liquidity amid Q2 revenue of $38.1 million, up 132% year-over-year from Greenbrook integration, yet gross margins dipped to 46.6% due to clinic operations. The deal extends the $2 million minimum liquidity covenant through September 2026. Warrants for 225,000 shares sweeten the terms.
10-Q
Q2 FY2025 results
Neuronetics posted Q2 revenue of $38.1M, up 132% y/y from $16.5M, fueled by $23.0M in clinic revenue from the Greenbrook acquisition closed December 9, 2024, for $38.8M (cash/stock/settlements), recognizing $19.1M goodwill and $19.7M finite-lived intangibles amortized over 5-21 years; treatment sessions dipped 8% y/y to $10.8M, while system sales fell 13% y/y to $3.5M. Gross margin shrank to 46.6% from 74.0% amid the lower-margin clinic mix, with operating loss narrowing 5% y/y to $8.1M as G&A rose 98% y/y to $12.2M from integration costs, offset by 20% y/y R&D cuts. YTD revenue hit $70.1M, up 107% y/y, with net loss widening to $22.5M or $(0.36) diluted EPS on 63.8M shares; cash burned $20.5M in operations, ending at $11.0M plus $6.5M restricted, backed by $60.0M debt (7% + SOFR, due July 2029) under compliant covenants. Revenue relies heavily on third-party payor reimbursements, vulnerable to policy shifts.
8-K
New CFO Appointment
Neuronetics appointed Steven Pfanstiel as Executive Vice President, Chief Financial Officer, and Treasurer on July 15, 2025, replacing retiring CFO Steve Furlong, who will advise through March 2026. Pfanstiel, with deep medtech and pharma finance experience from Marinus and Johnson & Johnson, joins with a $480,000 base salary, 50% target bonus, $10,000 sign-on, and 400,000 RSUs vesting over four years. The move bolsters financial leadership amid Greenbrook integration. Company reaffirms Q2 and full-year 2025 guidance, targeting positive cash flow in Q3. Smooth transition aids profitability push.
8-K
Annual meeting outcomes mixed
Neuronetics stockholders convened their annual meeting on May 22, 2025, with 81.38% turnout electing all seven director nominees and ratifying KPMG as auditors for 2025. They also approved executive compensation on an advisory basis. Yet the bid to scrap supermajority voting rules flopped, drawing 25.6 million against votes. This preserves entrenched governance amid ongoing operations.
8-K
Q1 revenue surges 84%
Neuronetics reported Q1 2025 revenue of $32.0 million, up 84% from $17.4 million last year, fueled by the Greenbrook acquisition that added $18.7 million in clinic revenue. Yet gross margin dipped to 49.2% from 75.1% due to lower-margin clinic operations, while net loss widened to $12.7 million from $7.9 million. CFO Steve Furlong will retire March 31, 2026, with a search underway. The company projects cash flow positivity in Q3 2025.
BWAY
Brainsway Ltd.
16.80+0.22
CLPT
ClearPoint Neuro Inc.
24.11-2.87
CVRX
CVRx, Inc.
10.81+0.09
EMED
Electromedical Technologies, In
0.00+0.00
INSP
Inspire Medical Systems, Inc.
75.17-2.00
NMTC
NeuroOne Medical Technologies C
0.79-0.03
NPCE
Neuropace, Inc.
10.13-0.49
NRXS
Neuraxis, Inc.
3.02+0.00
NXL
Nexalin Technology, Inc.
1.55+0.07
STME
Stimcell Energetics, Inc.
0.44+0.03